Astellas Pharma Inc. (YPH.F)

9,11 -0,09 (-0,98%) Al cierre: 09:49PM CEST

Astellas Pharma Inc.

2-5-1, Nihonbashi-Honcho
Chuo-Ku
Tokyo 103-8411
Japan
81 3 3244 3000
https://www.astellas.com

Sector(es): Healthcare
Sector: Drug Manufacturers - General
Empleados a tiempo completo: 

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Naoki Okamura BSc	President, CEO & Director	885,54k	N/A	1962
Mr. Atsushi Kitamura	Chief Financial Officer	N/A	N/A	N/A
Nobue Yasuda	General Manager of Finance & Accounting Department	N/A	N/A	N/A
Mr. Yoshitsugu Shitaka Ph.D.	Chief Scientific Officer & Senior Managing Executive Officer	N/A	N/A	N/A
Ms. Catherine B. Levitt	General Counsel	N/A	N/A	N/A
Mr. Katsuyoshi Sugita	Chief People Officer, Chief Ethics & Compliance Officer, EVP of HR and Representative Director	N/A	N/A	1967
Mr. Stig Ogata	Vice President of Corporate Communications	N/A	N/A	N/A
Ms. Collette Taylor	Senior Vice President of Human Resources	N/A	N/A	1963
Ms. Tatjana Dragovic	Senior VP and Head of Ethics & Compliance	N/A	N/A	N/A
Mr. Nobuaki Tanaka	President of Japan Commercial & Senior Corporate Executive	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en EUR.

Descripción

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.

Gobierno corporativo

El ISS Governance QualityScore de Astellas Pharma Inc., a día 1 de mayo de 2024, es 2. Las puntuaciones base son Auditoría: 1; Tablero: 2; Derechos de los accionistas: 6; Compensación: 1.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.